Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis (NCT07203391)

This trial is Currently recruiting

Registration number NCT07203391

Based on the established activity of Tebentafusp, and the promising action of Roginolisib, this trial combines the two drugs from cycle 4 onwards in patients with metastatic uveal melanoma.

Program & service

This trial is being run with the Cancer service, and as part of the Medical Oncology program.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Malaka Ameratunga

Key inclusion data

Histologically or cytologically confirmed metastatic or unresectable Uveal Melanoma patients. HLA-A*02:01 positive. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Currently undergoing first-line tebentafusp in recurrent/advanced/metastatic setting. Tebentafusp related toxicity, including cytokine release syndrome that has resolved to grade ≤ 1 as per CTCAE v5.0.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.